Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) was the target of some unusual options trading activity on Thursday. Stock traders bought 6,144 call options on the stock. This is an increase of 759% compared to the average volume of 715 call options.
Analyst Ratings Changes
A number of brokerages recently issued reports on MRTX. BMO Capital Markets dropped their price objective on shares of Mirati Therapeutics from $50.00 to $40.00 in a report on Thursday. Morgan Stanley reduced their target price on shares of Mirati Therapeutics from $60.00 to $50.00 and set an “equal weight” rating on the stock in a report on Friday, January 27th. VNET Group reiterated a “maintains” rating on shares of Mirati Therapeutics in a research report on Thursday, May 11th. Barclays lowered their price objective on shares of Mirati Therapeutics from $90.00 to $75.00 in a research note on Thursday. Finally, StockNews.com began coverage on shares of Mirati Therapeutics in a report on Thursday, May 18th. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Mirati Therapeutics currently has an average rating of “Hold” and a consensus price target of $76.93.
In related news, EVP Jamie Christensen sold 619 shares of the business’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $45.29, for a total value of $28,034.51. Following the completion of the transaction, the executive vice president now directly owns 124,123 shares in the company, valued at approximately $5,621,530.67. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.47% of the company’s stock.
Institutional Investors Weigh In On Mirati Therapeutics
Mirati Therapeutics Price Performance
Shares of Mirati Therapeutics stock opened at $38.40 on Friday. Mirati Therapeutics has a one year low of $32.96 and a one year high of $101.30. The stock’s 50-day moving average is $42.22 and its 200 day moving average is $49.69. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -2.96 and a beta of 1.04.
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($3.18) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.29. Mirati Therapeutics had a negative return on equity of 71.90% and a negative net margin of 3,901.06%. The company had revenue of $7.17 million during the quarter, compared to the consensus estimate of $4.80 million. During the same period last year, the business posted ($3.40) earnings per share. Mirati Therapeutics’s revenue was up 910.9% on a year-over-year basis. On average, sell-side analysts expect that Mirati Therapeutics will post -12.66 EPS for the current fiscal year.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm’s products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on Mirati Therapeutics (MRTX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.